Xu Diyong 4

What Happened

• Xu Diyong, reported as a 10% owner of Q32 Bio, purchased a total of 1,875,000 shares of Q32 Bio common stock in a private placement on May 28, 2026. The purchases were made in two tranches: 1,250,000 shares and 625,000 shares, each at $8.00 per share, for a combined cash outlay of $15,000,000. This was a purchase (transaction code P) — a direct investment into the company rather than a sale.

Key Details

• Transaction date: May 28, 2026. Filing date: June 1, 2026 (Accession 0000947871-26-000594). Filing appears timely (filed within two business days).
• Prices and amounts: 1,250,000 shares @ $8.00 ($10,000,000) and 625,000 shares @ $8.00 ($5,000,000); total 1,875,000 shares for $15,000,000.
• Purchase type: Private placement (per footnote F1 — shares purchased from the issuer).
• Shares owned after transaction: Not specified in the excerpt provided (see the full Form 4 for post-transaction holdings).
• Other footnotes in the filing (F2–F4) concern OrbiMed-related entities and disclaimers of beneficial ownership for securities held by those funds; these relate to other reporting relationships in the filing and are not described as changing this purchase.
• Transaction code: P = Purchase.

Context

• This was a direct purchase from the company (private placement), which injects cash into Q32 Bio but is dilutive to existing shareholders since new shares were issued. Purchases by a 10% owner can signal an institutional/major investor increasing exposure, but filings are factual records — they do not explain motives.
• The filing met timing requirements based on the dates shown. For full post-transaction ownership and any additional disclosures, consult the complete Form 4 (Accession number above).